---
layout: page
---

# Sébastien Wieckowski, Ph.D. -- Resume

Immunologist, age 42, French/EU citizenship, married and one child

_See also a one-page visual resume PDF [here](resume_visual_84.pdf)_

## Summary

* PhD-qualified immunologist with 15 years of experience with a focus on tumor immunology and cancer vaccines
* Published 6 first author + 18 coauthor manuscripts in high-impact scientific journals, and filled 2 international patents
* Gained a valued experience at different responsability levels, leading numerous preclinical and clinical biomarker projects and developing innovative bioassays in biotech and pharma
* Strong skills in data analysis and bioinformatics, solid expertise in immunology-based assays, animal models, molecular and cellular biology, biochemistry and flow cytometry, and great ability to understand and take advantage of innovative technologies
* Supervised and mentored technicians and PhD students; responsible for multiple technical and IT platforms

## Contact details

* [e-mail](mailto:sbwiecko@gmail.com)
* [LinkedIn](https://linkedin.com/in/sbwiecko)
* [Google Scholar](https://scholar.google.com/citations?user=fzECT2QAAAAJ&hl=en)
* [ResearchGate](https://www.researchgate.net/profile/Sebastien_Wieckowski)
* [Twitter](https://twitter.com/sbwiecko)
* [GitHub](https://github.com/sbwiecko/)
* [Stack Overflow](https://stackoverflow.com/users/8275142/s%c3%a9bastien-wieckowski)

## Research Experience

* **Director Preclinical Development, Worg Pharmaceuticals (Nov 2021 -- present)**
  * Development of the preclinical program for our drug candidates
* **Principal Scientist, University of Applied Sciences (FHNW) and Roche External Employee (Dec 2018 -- Oct 2021)**
  * Development of innovative bioassays in immunology and cell and gene therapy (GMP)
* **Senior Scientist, VAXIMM AG _(part-time slashing_; Nov 2020 -- Oct 2021)**
  * Responsible for the personalized neoantigen vaccine assembly for the clinical trial NECVAXNEO1
* **Senior Scientist, VAXIMM AG (Feb 2016 -- Nov 2018)**
  * Preclinical development of the company's oral T cell vaccine pipeline (30+ studies)
  * Supervision of the immunomonitoring and histopathology GCLP analyses of our phase I/II clinical trials.
  * Business development (industry, academic collaborations) and management of our CRO partner portfolio
  * Regular and active participation to our Company Board and internal meetings + international congresses.
* **Parental leave (Mar 2015 -- Jan 2016)**
  * Provided care for my baby
  * Completed full renovation of a house within budget:
    * Coordinated and scheduled the activities of 10+ contractors
    * Partnered with local community members to gain planning approvals
    * Undertook courses to gain specific technical skills in plumbing, electricity etc.
  * Updated and extended professional skills in physiology, biostatistics, and programming
* **Roche Postdoctoral Fellow/Scientist, Roche Glycart/University Hospital Basel (Mar 2012 -- Feb 2015)**
  * Led a challenging project on the assessment of a novel tumor stroma-targeted IL-2-variant immunocytokines with anti-cancer therapeutics and immunomodulatory antibodies through T- and NK-cells in the preclinical genetically engineered Krasmut/p53-/- mouse model of non-small cell lung cancer. Cancer Immunology (Prof. A. Zippelius), Department of Biomedicine (ZLF), Universitätsspital Basel, Switzerland; and Roche Glycart (Mentor Dr. C. Klein), Schlieren, Switzerland. Supported by the Roche Postdoc Fellowship (RPF) Program.
* **Postdoctoral Scientist, Ludwig Institute for Cancer Research (Oct 2007 -- Feb 2012)**
  * Led a great translational immuno-oncology project on the characterization of CD8 T cell responses after therapeutic vaccination of melanoma patients with antigenic peptides (prospective phase I clinical trial). Ludwig Institute for Cancer Research Lausanne branch (Prof. P. Romero), and the Centre Pluridisciplinaire d'Oncologie, Faculté de Biologie et de Médecine, University of Lausanne (UNIL), Switzerland. Supported by Oncosuisse, and Wilhelm Sander Stiftung.
* **Postdoctoral fellow/Visiting scientist, University Hospital Lyon (Jun 2007 -- Sep 2007)**
  * Initiated a national project on the transduction of human DCs with adenovirus and enhanced presentation of HIV-1 epitopes; applications to the potentiation of an anti-HIV-1 response. Laboratory of Virology & Viral Pathogenesis (Prof. P. Boulanger), CNRS UMR 5537, Faculty of Medicine RTH Laennec, Lyon, France. Continuation of the collaborative project started in Jan. 2006. Supported by a grant from ANRS.
* **Ph.D. student (immunology), University of Strasbourg (Oct 2003 −- May 2007)**
  * Development of innovative functional CD40L mimetics based on C3-symmetric peptide scaffolds, at the interface of chemistry and biology; applications to cancer vaccines and immunotherapy. Immunologie et Chimie Thérapeutiques (Prof. S. Müller), Institut de Biologie Moléculaire et Cellulaire (IBMC), CNRS UPR 9021, Strasbourg, France. Supervised by Prof. S. Fournel and Dr. G. Guichard. Supported by the Ministère de l'Education Nationale de la Recherche et des Technologies (MENRT), and the Fondation pour la Recherche Médicale (FRM).
* **IT support / Responsible for the hardware park of the research unit (Jul 2004 −- May 2007)**
  * Computer assistance to the users (software installation, workshops, hardware fix, basic network troubleshooting), and deploying/optimizing of new hardware (computers and instruments). Immunologie et Chimie Thérapeutiques (Prof. S. Müller), Institut de Biologie Moléculaire et Cellulaire (IBMC), CNRS UPR 9021, Strasbourg, France.

## Education and Degrees

* **Ph.D. in Immunology**, Université Strasbourg I, France, 2007.
* **Master Degree in Health Biology** (DEA Biologie-Santé), Université Montpellier II, France, 2003.
* **M.Sc. (Maîtrise) in Biochemistry + Organic Chemistry**, Université Montpellier II, France, 2002.
* **B.Sc. (Licence) in Biochemistry** _Summa Cum Laude_, ranked 1st/112, Université Montpellier II, France, 2001.

## Publications, Patents, Communications and Teaching

### [Publications](https://www.ncbi.nlm.nih.gov/pubmed/?term=sebastien+wieckowski)

24. **Wieckowski S**, Avenal C, Orjalo AV, Gygax D, and Cymer F.
Toward a Better Understanding of Bioassays for the Development of Biopharmaceuticals by Exploring the Structure-Antibody-Dependent Cellular Cytotoxicity Relationship in Human Primary Cells. Front Immunol 2020; 11: 552596.
23. Kashyap AS, Fernandez-Rodriguez L, Zhao Y, Monaco G, Trefny MP, Yoshida N, Martin K, Sharma A, Olieric N, Shah P, Stanczak M, Kirchhammer N, Park SM, **Wieckowski S**, Laubli H, Zagani R, Kasenda B, Steinmetz MO, Reinecker HC, Zippelius A. 
GEF-H1 Signaling upon Microtubule Destabilization Is Required for Dendritic Cell Activation and Specific Anti-tumor Responses. Cell Rep. 2019; 28(13):3367.
22. Schmitz-Winnenthal FH, Hohmann N, Schmidt T, Podola L, Friedrich T, Lubenau H, Springer H, **Wieckowski S**, Breiner KM, Mikus G, Büchler MW, Keller AV, Koc R, Springfeld C, Knebel P, Bucur M, Grenacher L, Haefeli WE, Beckhove P. 
A phase 1 trial extension to assess immunologic efficacy and safety of prime -- boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer. OncoImmunology. 2018; 7(4):e1303584.
21. Gannon PO, **Wieckowski S**, Baumgaertner P, Hebeisen M, Allard M, Speiser DE, Rufer N. 
Quantitative TCR avidity assessment by NTAmers reveals melanoma antigen-specific T cell repertoires enriched for high functional competence. J Immunol. 2015; 195:356.
20. **Wieckowski S**, Hemmerle T, Savic Prince S, Dolder Schlienger B, Hillinger S, Neri D, Zippelius A.
Therapeutic efficacy of the F8-IL2 immunocytokine in a metastatic mouse model of lung. Lung Cancer. 2015; 88(1):9.
19. Gupta B, Iancu EM, Gannon PO, **Wieckowski S**, Baitsch L, Speiser DE, Rufer N.
Simultaneous coexpression of memory-related and effector-related genes by individual human CD8 T cells depends on antigen specificity and differentiation. J Immunother. 2012; 35(6):488.
18. Lövgren T, Baumgaertner P, **Wieckowski S**, Devêvre E, Guillaume P, Luescher I, Rufer N, Speiser DE.
Enhanced cytotoxicity and decreased CD8 dependence of human cancer-specific T cells after vaccination with low peptide dose. Cancer Immunol Immunother. 2012; 61(6):817.
17. Leimgruber A, Ferber M, Irving M, **Wieckowski S**, Hussain-Kahn H, Derré L, Rufer N, Zoete V, Michielin O.
TCRep 3D: an automated in silico approach to study the structural properties of TCR repertoires. PloS ONE. 2011; 6: e26301.
16. **Wieckowski S**, Speiser DE, Gupta B, Iancu EM, Baumgaertner P, Baitsch L, Michielin O, Romero R, Rufer N.
Single cell analysis reveals similar functional competence of dominant and non-dominant CD8 T-cell clonotypes. Proc Natl Acad Sci USA. 2011; 108:15318-15323.
1.  Baitsch L, Baumgaertner P, Devêvre E, Raghav SK, Legat A, Barba L, **Wieckowski S**, Bouzourene H, Deplanke B, Romero P, Rufer N, Speiser DE.
Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients. J Clin Invest. 2011; 121:2350-2360.
14. Iancu EM, Baumgaertner P, **Wieckowski S**, Speiser DE, Rufer N.
Profile of a serial killer: cellular and molecular approaches to study individual cytotoxic T-cells following therapeutic vaccination. J Biomed Biotech. 2011; 2011:452606.
13. **Wieckowski S**, Baumgaertner P, Corthésy P, Voelter V, Romero P, Speiser DE, Rufer N.
Fine structural variations of αβTCRs selected by vaccination with natural versus altered self-antigen in melanoma patients. J Immunol. 2009; 183:5397-5406.
12. Jandus C, Bioley G, Dojcinovic D, Derré L, Baitsch L, **Wieckowski S**, Rufer N, Kwok WW, Tiercy JM, Luescher IF, Speiser DE, Romero P.
Tumor antigen specific regulatory CD4 T-cells identified in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts. Cancer Res. 2009; 69:8085-8093.
11. Partidos CD, Hoebeke J, **Wieckowski S**, Chaloin O, Bianco A, Moreau E, Briand JP, Desgranges C, Muller S.
Immunomodulatory consequences of ODN CpG-polycation complexes. Methods. 2009; 49:328-333.
10. Rich LR, Papalia GA, Flynn PJ... **Wieckowski S**... Myszka DG.
A global benchmark study using affinity-based biosensors. Anal Biochem. 2009; 386:194-216.
9. Trouche N, **Wieckowski S**, Sun W, Chaloin O, Briand JP, Hoebeke J, Fournel S, Guichard G.
Small trivalent architectures mimicking homotrimers of the TNF superfamily member CD40L: delineating the relationship between structure and effector function. JACS. 2007; 129:13480-13492.
8. Habib M, Chamekh M, Rivas MN, **Wieckowski S**, Sun W, Bianco A, Trouche N, Chaloin O, Dumortier H, Goldman M, Guichard G, Fournel S, Vray B.
Small molecule CD40L mimetics promote control of parasitemia by enhancing CD8+ cells production of interferon-γ during experimental Trypanosoma cruzi infection. J Immunol. 2007; 178:6700-6704.
7. **Wieckowski S**, Trouche N, Chaloin O, Guichard G, Fournel S, Hoebeke J.
Cooperativity in the interaction of synthetic CD40L mimetics with CD40 and its implication in cell signaling. Biochem. 2007; 46:3482-3493.
6. Kostarelos K, Lacerda L, Pastorin G, Wu W, **Wieckowski S**, Luangsivilay J, Godefroy S, Pantarotto D, Briand JP, Muller S, Prato M, Bianco A.
Cellular uptake of functionalized carbon nanotubes is independent of functional group and cell type. Nat Nanotech. 2007; 2:108-113.
5. Bianco A, Fournel S, **Wieckowski S**, Hoebeke J, Guichard G.
Solid-phase synthesis of CD40L mimetics. Org Biomol Chem. 2006; 4:1461-1463.
4. Pastorin G, Wu W, **Wieckowski S**, Briand JP, Kostarelos K, Prato M, Bianco A.
Double functionalization of carbon nanotubes for multimodal drug delivery. Chem Commun (Camb). 2006; 21:1182-1184. Recognized as within the top 50 articles published in 2006 in Chem Commun.
3. **Wieckowski S**, Fournel S, Sun W, Trouche N, Dumortier H, Bianco A, Chaloin O, Habib M, Peter JC, Schneider P, Vray B, Toes RE, Offringa R, Melief CJ, Hoebeke J, Guichard G.
C3-symmetric peptide scaffolds are functional mimetics of trimeric CD40L. Nat Chem Biol. 2005; 1:377-382. _Research Highlights: Drug Discovery: Immune booster. Nature. 2005; 438:132. Immunotherapy: TNFR superfamily trimers. Nat Rev Drug Discov. 2006; 5:1._
1. Wu W, **Wieckowski S**, Pastorin G, Benincasa M, Klumpp C, Briand JP, Gennaro R, Prato M, Bianco A.
Targeted delivery of amphotericin B to cells by using functionalized carbon nanotubes. Angew Chem Int Ed Engl. 2005; 44:6358-6362.
1. Young LE, Schnieke AE, McCreath KJ, **Wieckowski S**, Konfortova G, Fernandes K, Ptak G, Kind AJ, Wilmut I, Loi P, Feil R.
Conservation of IGF2-H19 and IGF2R imprinting in sheep: effects of somatic cell nuclear transfer. Mech Dev. 2003; 120:1433-1442.

### Patents

2. Guichard G, Fournel S, Trouche N, **Wieckowski S**.
_Novel multimeric molecules, a process for preparing the same and the use thereof for manufacturing medical drugs._
   * Brevet Français 07/00809, déposant CNRS (05/02/2007)
   * International Application PCT/FR2008/000129 (04/02/2008)
   * International Publication WO/2008/110695 (18/09/2008)
1. Guichard G, Fournel S, Chaloin O, Trouche N, **Wieckowski S**, Hoebeke J.
_Novel multimeric CD40 ligands, method for preparing same and use thereof for preparing drugs._
   * Brevet Français 04/13331, déposant CNRS (15/12/2004)
   * International Application PCT/FR2005/03146 (15/12/2005)
   * International Publication WO/2006/064133 (22/06/2006)

### Communications (selection)

* **Wieckowski S**, Avenal C, Orjalo AV, Gygax D, and Cymer F.
A better understanding of bioassays -- comparison of binding assays, reporter gene assays and primary cell-based assays of glycoengineered monoclonal antibodies. BEBPA's Virtual 2021 EUR Bioassay Conference. Oral presentation.
* **Wieckowski S**, Podola L, Kobl I, Smetak H, Springer M, Nugues AL, Slos P, Broadmeadow A, Chesher C, Adda Berkane A, Wei M, Breiner K, Meichle A, Breiner K, Mansour M, Beckhove P, Lubenau H.
Modulating T cell immunity in tumors by targeting tumor-associated antigens, PD-L1 and neoantigens using a versatile live attenuated oral Salmonella DNA vaccination platform. AACR Annual Meeting, Chicago (USA), 2018. Poster 733.
* **Wieckowski S**.
Non-clinical safety, immunogenicity and antitumor efficacy of live attenuated Salmonella Typhimurium based oral T-cell vaccines. ASGCT 20th Annual Meeting, Washington, D.C (USA), 2017. Oral presentation #777.
* **Wieckowski S**, Podola L, Springer M, Broadmeadow A, Stevens P, Chesher C, Adda Berkane A, Wei M, Kobl I, Meichle A, Beckhove P, Breiner K, Lubenau H.
Non-clinical safety, immunogenicity and antitumor efficacy of live attenuated Salmonella Typhimurium-based oral T-cell vaccines VXM01m, VXM04m and VXM06m. AACR Annual Meeting, Washington, D.C. (USA), 2017. Poster 4558.
* **Wieckowski S**.
Using the immune system to treat cancer -- Could we cure cancer in the next ten years? European Health Science Match; Heidelberg (Germany), 2016. Oral presentation #85.
* **Wieckowski S**.
Therapeutic synergism of a novel tumor stroma-targeted IL-2- variant immunocytokine with standard-of- care anti-cancer therapeutics and immunomodulatory antibodies in the genetically engineered KP mouse model of non-small cell lung cancer. Roche Symposium of the Roche Postdoc Fellowship Program; Basel (Switzerland), 2013. Oral presentation #216.
* **Wieckowski S**, Müller P, Freimoser-Grundschober A, Savic S, Fink Y, Karanikas V, Umana P, Pisa P, Klein C, Zippelius A.
Therapeutic synergism of a novel tumor stroma-targeted IL-2-variant immunocytokine with standard-of-care anti-cancer therapeutics and immunomodulatory antibodies in the genetically engineered KP mouse model of non-small cell lung cancer. Roche Symposium of the Roche Postdoc Fellowship Program; Penzberg (Germany), 2012. Poster RPF ID 216.
* **Wieckowski S**, Baumgaertner P, Corthésy P, Voelter V, Romero R, Speiser D, Rufer N.
Characterization of CD8+ T cell responses induced by vaccination with Melan-A peptides in melanoma patients. Role of Inflammation in Oncogenesis and Immune Escape in Cancer joint Keystone Symposia, Keystone, CO (USA), 2010. Poster J5-338.
* **Wieckowski S**, Baumgaertner P, Corthésy P, Voelter V, Romero R, Speiser D, Rufer N.
Molecular characterization of CD8+ T cell responses in melanoma patients following therapeutic peptide vaccination. 4e Journée Scientifiques du Cancéropôle Lyon Auvergne Rhône-Alpes, Archamps (France), 2009. Poster P70. Best Poster Award (see CLARA report on page 17).
* **Wieckowski S**, Baumgaertner P, Corthésy P, Voelter V, Romero R, Speiser D, Rufer N.
CD8 T cell responses in melanoma patients following therapeutic peptide vaccination. 1st Swiss Immunotherapy Symposium, Lausanne (Switzerland), 2009. Oral presentation.
* **Wieckowski S**, Trouche N, Hoebeke J, Guichard G, Fournel S.
Application of functional small synthetic CD40L mimetics to lymphoma therapy. 1st joint meeting of European National Societies of Immunology, 16th European Congress of Immunology, Paris (France), 2006. Poster PD-3918.
* **Wieckowski S**, Trouche N, Sun W, Chaloin O, Hoebeke J, Guichard G, Fournel S.
Improvements of small synthetic CD40L mimetics and their effects on cell signaling. MipTec -- the 9th Leading European Drug Discovery Event, Basel (Switzerland), 2006. Poster P89.
* **Wieckowski S**, Trouche N, Sun W, Chaloin O, Hoebeke J, Guichard G, Fournel S.
Mimes fonctionnels de CD40L et applications thérapeutiques. Rencontres mensuelles du cercle des immunologistes de Strasbourg, Strasbourg (France), 2006. Oral presentation.
* **Wieckowski S**, Trouche N, Chaloin O, Bianco A, Hoebeke J, Dumortier H, Guichard G, Fournel S.
A synthetic multimeric ligand of CD40 is able to mimic effector functions of the natural CD40L. Congrès Annuel de la Société Française d'Immunologie, Paris (France), 2004. Poster P50.

### Congress Abstracts

7. **Wieckowski S**, Podola L, Smetak H, Nugues AL, Slos P, Berkane AA, Wei M, Breiner K, Meichle A, Beckhove P, Mansour M, Lubenau H.
Modulating T cell immunity in tumors by targeting PD-L1 and neoantigens using a live attenuated oral Salmonella platform. Cancer Res. 2018; 78(13 Supplement):733-733.
6. Wick W, Wick A, Sahm F, Riehl D, von Deimling A, Bendszus M, Kickingereder P, Bonekamp D, Beckhove P, Schmitz-Winnenthal FH, Jungk C, **Wieckowski S**, Podola L, Herold-Mende C, Unterberg A, Platten MJ.
VXM01 phase I study in patients with progressive glioblastoma: Final results. J Clin Oncol. 2018; 36(15_suppl):2017-2017.
5. **Wieckowski S**, Smetak H, Kobl I, Podola L, Nugues AL, Slos P, Berkane AA, Wei M, Breiner K, Meichle A, Mansour M, Schroff M, Beckhove P, Lubenau H.
Live attenuated oral Salmonella platform for effective T- and B-cell targeting of PD-L1. J Clin Oncol. 2018; 36(5_suppl):74-74.
4. **Wieckowski S**, Podola L, Springer M, Kobl I, Koob Z, Mignard C, Berkane AA, Wei M, Meichle A, Breiner K, Schroff M, Beckhove P, Lubenau H.
Immunogenicity and antitumor efficacy of live attenuated Salmonella typhimurium-based oral T-cell vaccines VXM01m, VXM04m and VXM06m. Cancer Res. 2017; 77(13S):Abstract nr 4558.
3. Wick W, Wick A, Nowosielski M, Sahm F, Riehl D, Arzt M, von Deimling A, Bendszus M, Kickingereder P, Bonekamp D, Beckhove P, Schmitz-Winnenthal FH, Jungk C, **Wieckowski S**, Herold-Mende C, Lubenau H, Unterberg A, Platten MJ.
VXM01 phase I study in patients with resectable progression of a glioblastoma. J Clin Oncol. 2017; 35(15_suppl):2061-2061.
2. **Wieckowski S**, Springer M, Podola L, Broadmeadow A, Stevens P, Chesher CJ, Berkane AA, Wei M, Meichle A, Beckhove P, Breiner K, Lubenau H.
Non-clinical safety and antitumor efficacy of live attenuated Salmonella typhimurium-based oral T-cell vaccines VXM01m, VXM04m and VXM06m. Eur J Cancer. 2016; 69:S106.
1. Guichard G, Trouche N, **Wieckowski S**, Sun W, Chaloin O, Bianco A, Hoebeke J, Schneider P, Fournel S.
Rationally designed multivalent architectures for mimicking homotrimers of CD40L, a member of the TNF superfamily. Peptides for Youth: The Proceedings of the 20th American Peptide Symposium, Montreal (Canada), 2007. Adv Exp Med Biol. 2009; 611:355-357.

### Peer-reviewing

Active reviewer in Journal for ImmunoTherapy of Cancer, Cancer Immunology Immunotherapy, Cancers, Vaccines, Biomedicines, Immuno, International Journal of Molecular Sciences, and Biomolecules. See also [my ORCID record](https://orcid.org/0000-0001-8121-4446).

### Teaching

* Course Assistant in Immunology (Travaux Pratiques) for B.Sc. Biochemistry, Université Strasbourg I (2004 − 2007; 60 hours).
* Teaching Assistant in Immunobiology (Travaux Dirigés) for First College Degree in Biology, Université Strasbourg I (2005 − 2006; 30 hours).

### Fellowships and Grants (Applicant)

* Subvention de fin de thèse de la FRM, 1-year fellowship (15,000 €), 2007
* BSI Travel Award (£700), 2007
* ANRS Research Grant (2 years) -- Réseau DENDRADE (200,000 €), 2007
* ANRS Post-doc Fellowship (2 years) -- Réseau DENDRADE (45,000 €), 2007
* Wilhelm Sander-Stiftung Fellowship (80,000 CHF), 2010
* Roche Postdoc Fellowship Program extension 1 year (140,000 CHF), 2013
* Freiwillige Akademische Gesellschaft ½ year (53,000 CHF), 2013

## Technical skills

* **Immunology** -- Manipulation of human blood (PBMC isolation, generation of DCs, preparation of serum), purification of T and NK cells and monocytes from animal tissues (Ficoll, magnetic sorting), establishment of human T and B cell clones after FACS (Vantage, Aria), differentiation of macrophages, imaging flow cytometry (Amnis), 51Cr-release assay and BATDA (CTL, tumor recognition), engineering of human CD8+ T-cells with lentiviral vectors, TCR binding kinetics measured with peptide/MHC tetramers, production and purification of antibodies (hybridoma, serum, ascites), ELISA (direct, indirect, sandwich, inhibition), cytokine ELISpot (Bioreader 5000) and multiplex bead-based immunoassays.
* **Cell biology** -- Multicolor flow cytometry including the BD LSR I, II and Fortessa, Accuri C6, FACScan, Calibur, Array, and the Beckman Coulter CyAn and Gallios systems, intracellular staining (cytokines, cell signaling, calcium), transient and stable transfection, RNAi, proliferation (3H-thymidine, CFSE) and cell cycle analysis (propidium iodide), measurement of apoptosis (Annexin V/PI, DiOC6(3), TUNEL), culture of adherent and non-adherent cells, 3D-culture, epifluorescence and confocal microscopy, time-lapse video microscopy, live imaging, fluorescent IHC/H&E staining of frozen tissue sections, AAV biology.
* **Animal experimentation** -- Injections of drugs and tumor xenografts (iv, sc, po, im), follow-up of tumor growth, survival, intratracheal, intranasal and intrathoracic applications (induction of lung adenocarcinoma in K-ras/p53 GEMM), blood sampling, collection of diverse organs and lymphoid tissues, counting of metastatic foci on the lung (KP, Renca, CT26 and B16 models), maintenance and needs of lab rodents, genotyping, SPECT/CT small animal imaging (Bioscan). Responsible for animal licenses.
* **Molecular biology** -- (sc)RNA-Seq, DNA/RNA isolation, various PCR techniques, RT-PCR, single cell gene expression analysis, TCR spectratyping, DNA sequencing, droplet digital PCR, standard molecular cloning techniques, preparation of lentiviral particles, expression and purification of recombinant proteins in bacteria and insect cell systems, Southern blotting, Northern blotting, functional promoter analysis (promoter-reporter construct, site-directed mutagenesis, DNase footprinting assay), whole genome microarray (Agilent).
* **Biochemistry** -- Surface plasmon resonance (BIAcore 3000), dynamic light scattering (Dynapro), SDS-PAGE, Western/dot blotting, 2D gel-electrophoresis, size exclusion chromatography, basic experience in organic chemistry (solid-phase peptide synthesis, mass spectroscopy).

## Professional Development and Training (Certificates)

* **Machine learning in python** with scikit-learn. INRIA, France (2021).
* Introduction to **statistics with Python**. Swiss Institute of Bioinformatics, Switzerland (2021).
* **Docker and Singularity** for reproducible research. Swiss Institute of Bioinformatics, Switzerland (2021).
* Version Control with **Git**. Swiss Institute of Bioinformatics, Switzerland (2021).
* **Transcriptomics Analysis**. Swiss Institute of Bioinformatics, Switzerland (2021).
* **(sc)RNAseq Data Analysis**, _full semester (CAMB714)_. PennVet, University of Pennsylvania, USA (2020).
* **SQL** Fundamentals Track. DataCamp, Belgium (2020).
* Bio-informatique pour la **Génomique Médicale**. CEA, Université de Paris, France (2020).
* **IBM Data Science** (Methodology, SQL, Visualization, Machine Learning). IBM, USA (2019-2020).
* **Mathematics for Machine Learning**. Imperial College London, UK (2019).
* Using **Python for Research**. Harvard University, USA (2018).
* Introduction à la **statistique avec R**. Faculté de Médecine, Université Paris Sud, France (2018).
* **Reproducible Research**: Methodological Principles for Transparent Science. INRIA, France (2018).
* **Data Scientist with Python** Career Track. DataCamp, Belgium (2017-2018).
* **SME Instrument Applicants** Training. Euresearch, Bern, Switzerland (2018).
* **Shell Bash**. Université de la Réunion, France (2018).
* **Python 3**, from basics to advanced concepts (9 weeks). Université Côte d'Azur, France (2018).
* **Human histology** (6 weeks). Université de Médecine de Liège, Belgium (2017).
* **Python for Data Science and Machine Learning** Bootcamp (12 weeks). Udemy (2017).
* **Bioinformatics**: Genomes and Algorithms. INRIA, France (2017).
* **LTK Module 2** -- Education and Training of Persons Conducting Animal Experiments. University of Zurich, Switzerland (2012). Accreditation as Study Director (Kantonale Tierschutzfachstelle, Veterinäramt Basel-Stadt).
* **Animal Experimentation and Small Animal Surgery** (mouse and rat). Université Strasbourg I, France (2007).
* Fluorescence and Compensation in **Multicolor Cytometry**. Association Française de Cytométrie, Paris, France (2005).
* **Proteomics**. Institut de Biologie Moléculaire et Cellulaire, Strasbourg, France (2005).
* **Confocal Microscopy**. Institut de Biologie Moléculaire des Plantes, Strasbourg, France (2004).
* **Pain in Animals**. Institut de Physiologie et de Chimie Biologique, Strasbourg, France (2004).

## Computer skills

* Excellent knowledge of **Microsoft Windows** up to version 11 and **Linux**, including **Powershell and Bash** shells, e.g., WSL2.
* Computer-savvy with strong programming capabilities (**Python 3, R**, C++, Julia, BASIC). **SQL** and noSQL.
* **Data analysis and visualization** with Python (NumPy, SciPy, pandas, matplotlib, seaborn, Bokeh, plotly, and Machine Learning with scikit-learn), and **R (RStudio)**; Visual Studio Code, Git, Docker.
* Collaborative/interactive working and presentations with **Jupyter notebook, Markdown, Dash** and GitLab.
* **Advanced Micrsoft Office**, i.e., Word, Excel with VBA and Python, PowerPoint, Access with SQL, OneNote, Teams, and SharePoint.
* Specialized tools, e.g., Photoshop, Prism, FlowJo, FCS Express, DIVA, Kaluza, GeneSpring, Fiji (ImageJ), Zotero, Clone Manager etc.
* **Bioinformatics**, i.e., online tools and databases, R and Python libraries incl. Bioconductor and biopython.
* **openBIS** digital notebook, and other data management, labnotebook and inventory management systems

## Languages
  * **French**, native
  * **English**, full professional proficiency
  * **German**, elementary proficiency (learned in high school)
  * **Polish**, elementary proficiency

## Others

* Solid knowledges/self-educated in **electronics**, including basics and integrated circuits, digital electronics, microcontrollers and microprocessors (Arduino and Raspberry Pi), setup of a web app stack (Flask, ngnix), databases for recording data from various sensors, etc.
* When I do not play with my kid, I mostly focus on DIY and gardening, **running 10-21.1K**, tennis, DJing (electronic music) and hiking.
